Probiotic Efficacy Evaluation Service in Immune Disorder Models

Connecting Probiotic Candidates to Immune-Relevant Preclinical Evidence

Probiotic candidates can influence innate and adaptive immunity at the same time, yet a change in one cytokine rarely explains whether an intervention is suppressing pathological inflammation, restoring immune competence, or shifting immune balance in an undesirable direction. Teams therefore need disease-relevant models and coordinated endpoints that reveal both efficacy and immunomodulatory direction.

Demonstrating efficacy and defining mechanism in a living system are critical to confident candidate selection and commercialization planning. At Creative Biolabs, we provide scientifically rigorous preclinical studies in well-characterized immune disorder models, integrating immune phenotyping, tissue pathology, gut barrier function, microbiome composition, and microbial metabolites to create a coherent view of each probiotic candidate's biological impact.

One study, multiple decision layers

Align the immune disorder model, administration plan, disease endpoints, immune direction, barrier response, microbiome shift, and mechanism hypotheses before the study begins.

Comprehensive Immune Disorder Animal Model Services for Probiotic Efficacy Evaluation

We design customized studies for novel strains, defined consortia, and formulated probiotic products. Each program connects a fit-for-purpose disease model with controlled dosing, longitudinal clinical observations, immune and tissue endpoints, microbiome or metabolite analysis, and a reporting plan built around the client's advancement question.

Inflammatory Bowel Disease Models

DSS-induced colitis, acute or chronic: epithelial injury, disease activity, mucosal inflammation, and recovery dynamics.
TNBS-induced colitis: Th1-skewed, transmural inflammation relevant to Crohn's disease-like biology.
IL-10 knockout mice: spontaneous microbiota-sensitive colitis driven by loss of anti-inflammatory control.

Autoimmune Disease Models

Experimental autoimmune encephalomyelitis: clinical scoring, central nervous system inflammation, and demyelination.
Collagen-induced arthritis: joint swelling, inflammatory mediators, immune-cell profiles, and tissue damage.
Pristane-induced lupus or MRL/lpr mice: systemic autoimmunity, autoantibodies, organ pathology, and cytokine networks.
Non-obese diabetic mice: autoimmune diabetes incidence, insulitis, and immune tolerance endpoints.

Allergy and Hypersensitivity Models

OVA-induced asthma or allergic airway inflammation: airway hyperresponsiveness, bronchoalveolar immune cells, IgE, Th2 cytokines, and lung histology.

DNCB- or OXA-induced contact hypersensitivity and atopic dermatitis: clinical skin scores, epidermal pathology, immune infiltration, cytokines, and barrier markers.

Probiotic Administration Strategy

Dosing regimen: evaluation of dose level, frequency, oral gavage or dietary inclusion, and viable count at administration.
Control architecture: vehicle, healthy or baseline control, disease control, and an appropriate positive-control intervention where justified.
Timeline and endpoints: prophylactic, concurrent, or therapeutic dosing windows linked to disease induction and sampling milestones.
Daily monitoring: body weight, general health, disease activity index, clinical scores, and model-specific welfare observations.

Questions Resolved Before Dosing

Is the intended effect prevention, disease attenuation, recovery, or immune restoration?
Does the product require a stabilization vehicle, food matrix, prebiotic, or encapsulated format?
Should exposure be confirmed by fecal recovery or strain-specific quantification?
Which sampling points are needed to separate early immune effects from downstream tissue repair?

Immunological Assays

Cytokine and chemokine ELISA; flow cytometry for T cells, B cells, macrophages, dendritic cells, and NK cells; qPCR or RNA-Seq; MPO activity; histopathology; IHC or immunofluorescence.

Gut Barrier Function

FITC-dextran permeability, ex vivo Ussing-chamber TEER, mucus and goblet-cell assessment, and ZO-1, occludin, claudin, or other tight-junction proteins by Western blot, IHC, or immunofluorescence.

Microbiome Analysis

16S rRNA Gene Sequencing, Shotgun Metagenomic Sequencing, and Targeted qPCR for community, functional, or strain-focused questions.

Metabolomics (Targeted/Untargeted)

SCFA quantification and broader fecal or serum metabolite profiling to connect microbial function with immune and barrier phenotypes.

Tissue Pathology

Model-specific scoring of inflammation, immune-cell infiltration, epithelial or organ injury, demyelination, joint damage, and tissue repair.

Integrated Interpretation

Statistical comparisons and cross-domain interpretation connect clinical scores with immune direction, tissue response, barrier integrity, microbial ecology, and exposure.

Sample	Typical Analyses	Decision Value
Feces or cecal contents	Microbiome, strain persistence, SCFAs, and metabolites	Exposure and microbial-ecology response
Colon or small intestine	Histology, gene and protein expression, lamina propria immune cells, and barrier markers	Local efficacy and gut-immune mechanism
Spleen and lymph nodes	Immune-cell phenotyping and ex vivo cytokine production	Systemic and adaptive immune direction
Blood, serum, or plasma	Cytokines, antibodies, immune markers, and metabolites	Circulating pharmacodynamic evidence
Disease-target organs	Brain or spinal cord in EAE, joints in CIA, pancreas in NOD mice, lung in asthma, or skin in dermatitis	Direct evidence at the site of pathology

10-20 weeks

Typical initiation-to-report range

Timing depends on model induction, acclimation, prophylactic or therapeutic dosing window, cohort size, longitudinal sampling, and analytical complexity. The customized proposal defines model-specific milestones, sample handoffs, data review points, and the final-report schedule.

Probiotic Efficacy Evaluation Workflow for Immune Disorder Models

The workflow translates the supplied five-stage process into a model-specific plan with defined decision gates and traceable analytical outputs.

01

Consultation & Study Design

Define objectives, probiotic strains or formulations, disease model, controls, dose levels, treatment window, and primary endpoints.

02

Animal Acclimation

Complete acclimation and baseline observations, verify administration material, randomize groups, and initiate probiotic dosing.

03

Laboratory Analysis

Collect and process scheduled samples, then execute selected immune, pathology, barrier, microbiome, and metabolite assays.

04

Data Interpretation

Perform statistical analysis and integrate efficacy, immune direction, exposure, barrier, and microbial-ecology findings.

05

Reporting

Deliver a detailed written report, processed figures, statistical summary, raw-data package, and recommended next steps.

Preclinical Probiotic Efficacy Study Deliverables and Data Packages

Deliverables are organized for scientific review, candidate comparison, mechanism planning, and efficient transfer into the next stage of development.

Deliverable Component	Content Specifications	Program Use
Comprehensive Study Report	Experimental design, materials, methods, quality observations, results, processed figures, statistical analysis, integrated interpretation, limitations, and conclusions.	Supports candidate selection and cross-functional review.
Raw and Processed Data Files	Clinical observations, sequencing FASTQ files where applicable, flow-cytometry plots or files, ELISA values, gene-expression outputs, histology images, and analysis-ready tables.	Enables transparent reanalysis and data-room preparation.
Statistical Analysis Summary	Predefined comparisons, effect estimates, significance testing, variability assessment, and concise interpretation of primary and exploratory endpoints.	Clarifies whether the study met its decision criteria.
Mechanism Evidence Map	A structured linkage among probiotic exposure, microbial shifts, metabolites, barrier effects, immune-cell or cytokine changes, tissue outcomes, and disease phenotype.	Prioritizes confirmatory MoA experiments and biomarkers.

Probiotic Study Sample Information and Project Submission Requirements

Start with the development question

Tell us whether the study must demonstrate efficacy, compare candidates, define a dose, identify a treatment window, resolve immune direction, or test a mechanism hypothesis. That decision shapes every downstream element.

Probiotic Strain Information

Species, strain designation, viable concentration, storage conditions, preparation instructions, and available safety information.

Formulation Details

Single strain or consortium, encapsulation, excipients, prebiotic components, food matrix, vehicle, and stability constraints.

Administration Preferences

Desired route, frequency, target dose range, dosing window, and any preliminary exposure or viability data.

Target Disorder and Hypothesis

Disease area, intended population, proposed immunological mechanism, key success criteria, and relevant in vitro findings.

Published Data Link Probiotic Treatment to Atopic Dermatitis Severity and Immune Responses

Recently published research assessed Lactobacillus acidophilus KBL409 in a house dust mite-induced atopic dermatitis model, an allergy system that allows probiotic activity to be read across visible disease, tissue injury, and immune markers. After oral administration, the investigators evaluated skin histology, dermatitis scores, serum IgE, Th1, Th2, and Th17 cytokine transcripts, IL-10, Foxp3, cecal microbiota, and microbial metabolites. This breadth is especially relevant when a candidate may affect both barrier pathology and adaptive immune polarization.

The figure shows H&E-stained skin, dermatitis severity, and serum IgE across experimental groups, linking a clinical-like phenotype with tissue and systemic immune outcomes. For probiotic teams, such aligned endpoints help distinguish a broadly supported efficacy signal from an isolated biomarker change and guide deeper studies of cytokine balance, Treg-associated responses, microbiome shifts, and metabolites. Creative Biolabs can build comparable allergy and hypersensitivity programs with customized dosing windows, longitudinal scoring, histopathology, immunoglobulin and cytokine panels, immune-cell analysis, microbiome profiling, and mechanism-focused sampling.

Histology, dermatitis severity, and serum IgE after probiotic intervention in a mouse allergy model. (OA Literature) — Fig.1 Effects of *L. acidophilus* KBL409 on AD symptoms. ^1,2

Advantages of Partnering with Creative Biolabs for Probiotic Immune Model Studies

Our value lies in making model execution, immune interpretation, microbial ecology, and program decisions work as one study rather than as disconnected assay outputs.

Gut-Immune Axis Expertise

Scientific understanding of microbiota-host interactions, mucosal immunity, and systemic immune regulation.

Validated Animal Models

Access to established inflammatory, autoimmune, allergy, and hypersensitivity study systems.

Comprehensive Analytics

Coordinated microbiology, immunology, histopathology, molecular biology, and metabolomics capabilities.

Customized Study Design

Flexible model, cohort, dose, timing, and endpoint plans aligned with scientific priorities and budget.

High-Quality Interpretation

Rigorous analysis and reporting that distinguish observation, association, and supported mechanism.

Ethical Research

Study planning and execution consistent with applicable animal-welfare and institutional requirements.

Dedicated Project Management

A clear point of contact coordinates study setup, milestones, data review, and reporting.

Translational Focus

Endpoints are chosen for their relevance to candidate decisions and future human-study hypotheses.

Applications of Probiotic Efficacy Studies in Immune Disorder Models

Probiotic Product Development

Compare novel strains, consortia, doses, and formulations for immune-related development goals.

Functional Food & Nutraceutical Research

Generate controlled preclinical evidence for immunomodulatory ingredients and finished products.

Biopharmaceutical Programs

Explore probiotics as standalone candidates or adjunctive approaches in inflammatory and autoimmune disease.

Translational Research

Access specialized in vivo capabilities for complex gut-microbiota and immune-system questions.

Disease Pathogenesis

Test how microbiome changes contribute to immune disorder development, severity, or recovery.

Mechanism of Action: How Probiotics Influence Immune Health

01

Modulation of Gut Microbiota Composition

Probiotics may compete with pathogens, produce antimicrobial substances, or support beneficial commensals, shifting microbial community structure and function.

02

Enhancement of Gut Barrier Integrity

Candidate activity may strengthen tight junctions and mucus defenses, reducing antigen or microbial-product translocation that can amplify immune responses.

03

Direct Interaction with Immune Cells

Signals from probiotics can influence dendritic cells, macrophages, T-cell subsets, B cells, and innate lymphocytes, altering cytokine production and immune balance.

04

Production of Bioactive Metabolites

SCFAs and other microbial metabolites can affect epithelial energy use, immune-cell differentiation, inflammatory tone, and host metabolism.

05

Modulation of Host Signaling Pathways

Candidate-specific effects may alter NF-kB, MAPK, inflammasome, or related pathways, producing measurable changes in immune genes and proteins.

Have you fully explored the potential of your selected probiotic product? Schedule a confidential consultation to receive a study concept tailored to your immune-disorder program.

Related Services for Probiotic Immune Efficacy Programs

Combine disease-model efficacy work with broader animal-study support, focused mechanism testing, and immune-cell analytics to build a more connected preclinical evidence package.

Probiotic Efficacy Evaluation: Preclinical Animal Study Services Broaden candidate evaluation across additional disease areas, study designs, and in vivo outcomes. Immune Modulation Based Probiotic Mechanism of Action Study Service in Animal Models Deepen mechanistic testing around immune-cell pathways, cytokine direction, and tissue responses. Immune & Cell Analysis Service for Live Biotherapeutic Products Add focused immune-cell phenotyping, functional assays, and cytokine analysis to LBP programs. Probiotic & Live Biotherapeutic Product Research Services Connect immune-model work with a wider probiotic and LBP research-development service platform.

Frequently Asked Questions

Yes. Our team can review the disease biology, intended probiotic mechanism, available model systems, induction method, expected timeline, and measurable endpoints. We may adapt an established model, add a disease-relevant challenge, or develop a feasibility plan for a customized approach.

Requirements depend on dose, administration frequency, study length, overage, viability testing, and formulation. We generally need strain identity, target viable count, storage and handling instructions, formulation composition, available safety information, and enough material for dosing preparation, quality checks, and contingency reserve.

The package can include raw and processed clinical observations, assay values, flow-cytometry outputs, sequencing files, histology images, statistical tables, publication-quality figures, and a comprehensive report that interprets efficacy, immune direction, barrier response, microbiome findings, and mechanism implications.

Yes. Dose-response arms and alternative treatment windows can be incorporated when cohort size, model duration, material availability, and primary endpoints support the comparison. We define the statistical contrasts and sampling points before study initiation so that exposure, early immune response, and downstream disease effects remain interpretable.

Other Resources

Creative Biolabs Live Biotherapeutics service brochure cover. (Creative Biolabs Original)

Creative Biolabs' Live Biotherapeutics - Brochure

Probiotic strain products for next-generation probiotic research brochure. (Creative Biolabs Original)

Probiotic Strain Products for NGP Research - Brochure

Custom Small-scale Probiotic Production - Brochure

Creative Biolabs live biotherapeutics video preview. (Creative Biolabs Original)

Live Biotherapeutics - Creative Biolabs - Video

References

Kim, Woon-ki, et al. "Lactobacillus acidophilus KBL409 ameliorates atopic dermatitis in a mouse model." Journal of Microbiology 62.2 (2024): 91-99. https://doi.org/10.1007/s12275-024-00104-5
Distributed under Open Access license CC BY 4.0, without modification.